Cardiotoxicity has emerged as a major side effect of doxorubicin (DOX) treatment, affecting nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non- cancer cause of death in DOX-treated patients. Although many different molecular mechanisms explaining the cardiac derangements induced by DOX were identified in past decades, the translation to clinical practice has remained elusive to date. This review examines the current understanding of DOX-induced cardiomyopathy (DCM) with a focus on mitochondria, which were increasingly proven to be crucial determinants of DOX-induced cytotoxicity. We discuss DCM pathophysiology and epidemiology and DOX-induced detrimental effects on mitochondrial function, dynamics, biogenesis, and autophagy. Lastly, we review the current perspectives to contrast the development of DCM, which is still a relatively diffused, invalidating, and life- threatening condition for cancer survivors.

Mitochondria and doxorubicin-induced cardiomyopathy. A complex interplay / Schirone, Leonardo; D'Ambrosio, Luca; Maurizio, Forte; Riccardo, Genovese; Schiavon, Sonia; Spinosa, Giulia; Giuliano, Iacovone; Valenti, Valentina; Frati, Giacomo; Sciarretta, Sebastiano. - In: CELLS. - ISSN 2073-4409. - 11:13(2022). [10.3390/cells11132000]

Mitochondria and doxorubicin-induced cardiomyopathy. A complex interplay

Leonardo Schirone
Primo
;
Luca D'Ambrosio;Sonia Schiavon;Giulia Spinosa;Giuliano Iacovone;Valentina Valenti;Giacomo Frati;Sebastiano Sciarretta
2022

Abstract

Cardiotoxicity has emerged as a major side effect of doxorubicin (DOX) treatment, affecting nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non- cancer cause of death in DOX-treated patients. Although many different molecular mechanisms explaining the cardiac derangements induced by DOX were identified in past decades, the translation to clinical practice has remained elusive to date. This review examines the current understanding of DOX-induced cardiomyopathy (DCM) with a focus on mitochondria, which were increasingly proven to be crucial determinants of DOX-induced cytotoxicity. We discuss DCM pathophysiology and epidemiology and DOX-induced detrimental effects on mitochondrial function, dynamics, biogenesis, and autophagy. Lastly, we review the current perspectives to contrast the development of DCM, which is still a relatively diffused, invalidating, and life- threatening condition for cancer survivors.
2022
DOX; anthracycline; cardiomyopathy; mitochondria; heart
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Mitochondria and doxorubicin-induced cardiomyopathy. A complex interplay / Schirone, Leonardo; D'Ambrosio, Luca; Maurizio, Forte; Riccardo, Genovese; Schiavon, Sonia; Spinosa, Giulia; Giuliano, Iacovone; Valenti, Valentina; Frati, Giacomo; Sciarretta, Sebastiano. - In: CELLS. - ISSN 2073-4409. - 11:13(2022). [10.3390/cells11132000]
File allegati a questo prodotto
File Dimensione Formato  
Schirone_Mitochondria_2022.pdf

accesso aperto

Note: https://www.mdpi.com/2073-4409/11/13/2000
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.62 MB
Formato Adobe PDF
1.62 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1649151
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 25
social impact